| Date Filed | Type | Description |
| 10/13/2023 |
8-K
| Quarterly results |
| 09/28/2023 |
8-K
| Quarterly results |
| 08/15/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/15/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/15/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/15/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor 10022",
"The Holder and any assignee, by acceptance of a Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face thereof.",
"AMENDMENT NO. 2 TO WARRANTS",
"WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.",
"Investor Contact:",
"Investor Contact:" |
|
| 08/14/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 08/10/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/07/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/03/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 07/31/2023 |
8-K
| Quarterly results |
| 07/25/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 07/10/2023 |
8-K
| Quarterly results |
| 06/16/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 06/02/2023 |
4
| STEINMAN LAWRENCE (Director) has filed a Form 4 on 180 Life Sciences Corp.|
Txns:
| Bought 18,000 shares
@ $1.226, valued at
$22.1k
|
|
| 06/01/2023 |
4
| McGovern Jr. Donald A. (Director) has filed a Form 4 on 180 Life Sciences Corp.|
Txns:
| Bought 10,000 shares
@ $1.147, valued at
$11.5k
|
|
| 05/23/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/23/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/19/2023 |
4
| Marrone Pamela G (Director) has filed a Form 4 on 180 Life Sciences Corp.|
Txns:
| Bought 7,082 shares
@ $1.06, valued at
$7.5k
|
|
| 05/19/2023 |
4
| Pamir Ozan (CFO) has filed a Form 4 on 180 Life Sciences Corp.|
Txns:
| Bought 5,162 shares
@ $1.01, valued at
$5.2k
|
|
| 05/18/2023 |
4
| Woody James N. (CEO) has filed a Form 4 on 180 Life Sciences Corp.|
Txns:
| Bought 40,000 shares
@ $1.03, valued at
$41.2k
|
|
| 05/15/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/15/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/12/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/09/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 05/05/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 04/28/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 04/26/2023 |
8-K
| Quarterly results |
| 04/14/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/23/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/22/2023 |
8-K
| Investor presentation |
| 01/20/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|